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ABSTRACT 13 
Carbon monoxide releasing molecules (CORMs) have been suggested as a new synthetic 14 
class of antimicrobials to treat bacterial infections. Here we utilised a novel EBOR-CORM-1 15 
([NEt4][MnBr2(CO)4]) capable of water-triggered CO-release, and tested its efficacy against a 16 
collection of clinical Pseudomonas aeruginosa strains that differ in infection-related 17 
virulence traits. We found that while EBOR-CORM-1was effective in clearing planktonic 18 
and biofilm cells of P. aeruginosa strain PAO1 in a concentration dependent manner, this 19 
effect was less clear and varied considerably between different P. aeruginosa cystic fibrosis 20 
(CF) lung isolates. While a reduction in cell growth was observed after 8 hours of CORM 21 
application, either no effect or even a slight increase in cell densities and the amount of 22 
biofilm was observed after 24 hours. This variation could be partly explained by differences 23 
in bacterial virulence traits: while CF isolates showed attenuated in vivo virulence and growth 24 
compared to strain PAO1, they formed much more biofilm, which could have potentially 25 
protected them from the CORM. Even though no clear therapeutic benefits against a subset of 26 
isolates was observed in an in vivo wax moth acute infection model, EBOR-CORM-1was 27 
more efficient at reducing the growth of CF isolate co-culture populations harbouring 28 
intraspecific variation, in comparison with efficacy against more uniform single isolate 29 
culture populations. Together these results suggest that CORMs could be effective at 30 
controlling genetically diverse P. aeruginosa populations typical for natural chronic CF 31 
infections and that the potential benefits of some antibiotics might not be observed if tested 32 
only against clonal bacterial populations. 33 
 34 
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1. INTRODUCTION 37 
The rapid emergence of multidrug-resistant bacteria is a global problem that is predicted to 38 
cause ten million deaths per year by 2050 (OÕNeill, 2014). Antibiotic resistance often evolves 39 
very quickly via de novo mutations and horizontal gene transfer (Normark and Normark, 40 
2002), and as a result, antibiotic discovery has not been able to replace all of the antibiotics 41 
that have now become ineffective (Brown and Wright, 2016). New methods and approaches 42 
for treating bacterial infections are thus urgently required.  43 
In recent years, carbon monoxide has emerged as a new potential therapeutic due to its 44 
properties as a homeostatic and cytoprotective molecule with important signalling 45 
capabilities (Motterlini and Otterbein, 2010). Carbon monoxide can be delivered via carbon 46 
monoxide releasing molecules (CORMs), which are small molecules that release carbon 47 
monoxide in response to certain environmental triggers such as enzymes (Stamellou et al., 48 
2014) or light (Jimenez et al., 2016). Nobre et al. first investigated the effect of CORMs on 49 
bacteria (Nobre et al., 2007) and found that CORM-2 and CORM-3 reduced the number of 50 
colony-forming units of Escherichia coli in minimal salts media and Staphylococcus aureus 51 
in Luria Broth (LB) media (Nobre et al., 2007). The CORM effects were stronger in near-52 
anaerobic conditions and the activation of CORM required direct contact between the 53 
molecule and its cellular targets (Nobre et al., 2007). Moreover, the effect of CORM-3 on 54 
Pseudomonas aeruginosa wild type strain PAO1 was investigated by Desmard et al. 55 
(Desmard et al., 2009), who found that treatment with the CORM reduced bacterial densities 56 
and increased the survival of immunocompromised mice during an infection. It has also 57 
previously been found that CORM-2 effectively reduces the densities of P. aeruginosa 58 
planktonic and biofilm cultures with wild type and clinical strains (Murray et al., 2012). 59 
Another study found that manganese-based Trypto-CORM is able to inhibit the growth of E. 60 
coli when exposed to photochemical stimulus (Ward et al., 2014), while in the dark it is 61 
active against Neisseria gonorrhoeae (Ward et al., 2017). In both cases, control experiments 62 
indicate that the CO liberated from the metal is responsible for the observed behaviour. 63 
However, most of the studies thus far have concentrated on exploring CORM effects on 64 
relatively short time span (less than 24 hours). Furthermore, although it has been established 65 
that many infections are polymicrobial, and that clinical bacterial pathogens can respond 66 
differently to CORMs than laboratory strains, no studies have explored CORM effects on 67 
bacterial co-cultures. 68 
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Cystic fibrosis (CF) is a genetically inherited disease which affects 1 in 2000 to 3000 69 
newborn infants in the EU (who.int, 2010). Patients with CF often develop a thick mucus in 70 
the lungs which they are unable to clear (Flume et al., 2010). This mucus makes patients 71 
susceptible to frequent and recurring bacterial chest infections and the presence of P. 72 
aeruginosa is often associated with increasing morbidity and loss of lung function (Pritt et 73 
al., 2007). One of the key features of P. aeruginosa is its capability to rapidly adapt to the 74 
lung environment and to become highly resistant to the antibiotics that are used to treat 75 
infections (Smith et al., 2006;Poole, 2011;Folkesson et al., 2012;Winstanley et al., 2016). As 76 
a result, P. aeruginosa populations show high levels of genetic variation within and between 77 
CF patients (Marvig et al., 2013;Williams et al., 2015;O'Brien et al., 2017). This includes 78 
phenotypic and genomic heterogeneity within genetically-related populations of P. 79 
aeruginosa derived from the same clonal lineage (Mowat et al., 2011;Workentine et al., 80 
2013;Williams et al., 2015). This variation might also affect the applicability of potential 81 
alternative therapies if it is linked with bacterial life-history traits that relate to potential 82 
resistance mechanisms. 83 
Here we synthesised and characterised a water-soluble CORM (EBOR-CORM-1), 84 
[NEt4][MnBr2(CO)4], and tested its effectiveness against P. aeruginosa strain PAO1 and a 85 
selection of P. aeruginosa CF isolates originating from a single sputum sample from the 86 
lungs of a CF patient, namely patient CF03 from previously published studies (Mowat et al., 87 
2011;Williams et al., 2015). Based on genome sequence data presented in a previous study, 88 
these CF isolates were classified into two genetically distinct Liverpool Epidemic Strain 89 
(LES) lineages, A and B (Williams et al., 2015;Williams et al., 2016), that differ regarding 90 
their virulence traits (O'Brien et al., 2017). These genetically diverged lineages have been 91 
shown to commonly coexist within individual patients and to share mutations via 92 
homologous recombination that potentially help strains to adapt to the airway during chronic 93 
infection (Williams et al., 2015). However, the implications of within-patient genetic 94 
variation have been seldom considered in the context of antimicrobial therapies. We 95 
hypothesised that effects of EBOR-CORM-1 could vary between different clinical isolates 96 
and lineages, and that the susceptibility of isolates could be linked to expression of some 97 
other bacterial virulence factors. We found that the CORM was effective in reducing both 98 
planktonic and biofilm cells of strain PAO1 in a density-dependent manner. However, 99 
CORM effects were more varied and generally weaker against clinical CF isolates. 100 
Regardless, CORM efficiently reduced the growth of CF strain lineage co-cultures, which 101 
suggest that CORMs could be effective at controlling genetically diverse P. aeruginosa 102 
infections. 103 
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2. MATERIALS AND METHODS 104 
Synthesis and properties of [NEt4][MnBr2(CO)4], EBOR-CORM-1 105 
EBOR-CORM-1 was synthesised as described previously (Angelici, 1964): Mn(CO)5Br (466 106 
mg, 1.69 mmol) and 330 mg (1.57 mmol) of [(C2H6)4N]Br were heated in 18 mL of absolute 107 
methanol under a nitrogen atmosphere at 50 ¡C for 1 hour. The methanol was then 108 
evaporated from the orange solution at the above temperature. The remaining yellow solid 109 
was dissolved in 40 mL of chloroform, and the solution was filtered under nitrogen. After 110 
adding 200 mL of hexane to the filtrate, the cloudy solution was allowed to stand under 111 
nitrogen for 2 hours. The air-stable yellow crystals were separated by filtration, washed with 112 
hexane, and dried under vacuum giving a yield of 88 % (636 mg). The compound was 113 
characterised via solid state IR spectroscopy recorded using a KBr disk. Four main bands 114 
were seen at 2090, 2001, 1984 and 1942 cm
-1
 and a small shoulder was seen at 1897 cm
-1
. 115 
This is consistent with the literature values (Angelici, 1964). In a chloroform solution of 116 
CORM four distinct bands were observed at 2092, 2015, 1987 and 1943 cm
-1
, again this is 117 
similar to previously reported literature values (Angelici, 1964). The change in the number of 118 
carbonyl bands between the solid and solution phase measurements typically reflects that 119 
different orientations are present in the solid state. The stability of the CORM in the solid 120 
state was tested by heating a sample to 50 ¡C and running ATR IR spectra at 1 hour intervals.  121 
Infrared detection of CO release from EBOR-CORM-1following dissolution in different 122 
solvents was conducted by dissolving 12 mg of CORM in 4 mL of solvent in a 25 mL round 123 
bottomed flask attached to vacuum evacuated gas IR cell via a closed tap. After 1 h of stirring 124 
the flask, the tap was opened to enable gas from the headspace of the flask to enter the IR 125 
cell. Carbon monoxide could then be identified via the distinctive gaseous IR signature of a 126 
double band, with fine rotational splitting, centred at 2150 cm
-1 
(Klein et al., 2014). The 127 
impact of different solvents can be quantified by comparison of the intensity of the CO bands 128 
to those from CO2, which is assumed to act as an effective internal standard. 129 
The release of CO from EBOR-CORM-1following dissolution in water was also followed via 130 
solution phase monitoring of the metal complexÕs IR bands. In contrast to chloroform, when 131 
EBOR-CORM-1was first dissolved in water only two main IR bands were observed at 2050 132 
and 1943 cm
-1
. In order to investigate activity of EBOR-CORM-1 in liquid culture media, we 133 
compared the effects of active and ÔinactivatedÕ CORM on the growth of PAO1 strain in LB 134 
media as described previously (Murray et al., 2012). Briefly, CORM was inactivated by 135 
storing a 2 mM CORM stock LB solution (10% v/v of standard LB concentration, i.e., the 136 
same that was used in all the experiments; see below) at room temperature for 24 hours. To 137 
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estimate the effect of CORM inactivation on PAO1 growth, we added 50 µL of freshly 138 
prepared 2 mM CORM, 50 µL of inactivated 2 mM CORM or 50 µL 10% v/v LB (control) to 139 
150 µL of PAO1 starter culture on 96-well microplate. All treatments were replicated five 140 
times and PAO1 growth monitored for 8 hours at 37 ûC with spectrophotometer (OD 600 nm; 141 
Tecan Infinite).  142 
Bacterial strains and culture media 143 
In this study we used P. aeruginosa strain PAO1 (ATCC 15692), the earliest archived isolate 144 
of the Liverpool Epidemic strain, LESB58 (Winstanley et al., 2009), and 19 clinical P. 145 
aeruginosa LES isolates from the same sputum sample of a chronically infected CF patient 146 
(Williams et al., 2015). The CF lung LES isolates originate from the sputum sample of one 147 
patient, identified as patient CF03 in previous studies, and consist of two genetically separate 148 
lineages A and B (Williams et al., 2015). Lineage A was represented by six isolates, namely 149 
isolates: 2, 5, 10, 19, 23 and 25. Lineage B was represented by 13 isolates, namely isolates: 1, 150 
6, 8, 17, 24, 26, 28, 32, 33, 34, 35, 36 and 37. Clinical isolates were collected with the 151 
consent of the patient and under institutional human investigation approval. All strains and 152 
isolates of P. aeruginosa were routinely cultured in liquid or solid LB media containing 10.0 153 
g tryptone, 5.0 g yeast extract and 10.0 g NaCl in 1 L of ultra-pure water (final pH adjusted to 154 
7.0 and 15 g of agar was used for solid media). For all experiments, starter cultures were 155 
prepared from cryofrozen stocks by streaking frozen stock culture onto LB plates. After 24 156 
hours growth, a single colony was selected and inoculated into 5 mL of liquid LB and grown 157 
overnight in a shaking incubator at 37 ûC in 50 mL centrifuge tubes. Overnight cultures were 158 
centrifuged at 4000 rpm (11.5 g) for 15 min (Eppendorf), the resultant pellets were suspended 159 
in 10% LB and bacterial densities adjusted to optical density at 600 nm of 0.066 before use 160 
(OD 600nm), equalling ~1 x 10
8
 cells mL
-1
. 161 
Measuring the effects of EBOR-CORM-1 concentration on P. aeruginosa PAO1 162 
strain 163 
We measured the effect of CORM concentration on P. aeruginosa PAO1 in four different 164 
ways. First, we examined how EBOR-CORM-1 affects PAO1 growth after both 8 and 24 165 
hours of inoculation in 10% LB media (bacteria and CORM inoculated at the same time). 166 
Additionally, we measured how effective EBOR-CORM-1 is at clearing both established 167 
planktonic and biofilm PAO1 cultures (bacteria pre-grown before adding EBOR-CORM-1). 168 
All measurements were conducted on 96-well microplates and each treatment was replicated 169 
5 times. A variety of EBOR-CORM-1 concentrations were tested by first preparing a 4 mM 170 
CORM stock solution (dissolving EBOR-CORM-1 in 10% LB media by vortexing for 30 s 171 
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and sonicating for 1.5 min). The stock solution was then sterilised with syringe filtration and 172 
serially diluted to result in 1 mM, 0.5 mM, 0.25 mM, 0.125 mM and 0 mM (control) EBOR-173 
CORM-1 concentrations and 1 x 10
8 
PAO1 cells mL
-1
 with final volume of 200 µl of media. 174 
The microplate was then incubated at 37 ûC for 24 hours.  175 
All replicate populations were sampled at 8 and 24 hours after the start of the experiment (20 176 
µl of samples) and serially diluted in sterile PBS on microplates to quantify the number of 177 
living versus dead cells by flow cytometry. Briefly, DAPI (4',6-diamidino-2-phenylindole for 178 
dead and living cells) and PI (Propidium iodide for dead cells) fluorescent stains (both from 179 
Sigma-Aldrich) were added to microplate wells with diluted bacterial samples at 180 
concentrations of 1 µg/mL and 50 µM, respectively. Plates were then incubated at room 181 
temperature for 1 hour before measuring cell densities with a Cytoflex flow cytometer and 182 
the CytExpert program. Every well was sampled for 60 s at fast speed setting. Gating of live 183 
and dead cells was performed by monitoring DAPI staining on the PB450 channel with the 184 
405 nm laser, and PI staining on the ECD channel of the 488 nm laser. Number of living cells 185 
was determined as total cells (DAPI) Ð dead cells (PI). 186 
To quantify the effects of EBOR-CORM-1 on established planktonic and biofilm cultures, 187 
PAO1 was first grown in the absence of CORM at 37 ûC for 48 hours. Cell cultures were then 188 
inoculated with stock CORM solution to reach the same final concentrations as above:  1 189 
mM, 0.5 mM, 0.25 mM, 0.125 mM and 0 mM (control) of CORM. The plate was incubated 190 
for four more hours at 37 ûC before sampling (20 µL), serial dilution and flow cytometry as 191 
described above. To quantify effects of EBOR-CORM-1 on biofilm, crystal violet was added 192 
to the remaining cell cultures at 10% v/v. After 15 min of incubation, the plate was rinsed 193 
with deionised water and solubilised with 228 µL ethanol per well. The biofilm was 194 
quantified by measuring absorbance at 600 nm. 195 
Measuring the effects of EBOR-CORM-1 on clinical P. aeruginosa isolates in 196 
mono- and co-cultures 197 
Similar to the PAO1 strain experiments, we measured the effect of EBOR-CORM-1on 198 
clinical P. aeruginosa isolates after 8 and 24 hours of inoculation in 10% LB media. We also 199 
measured the impact of growing the isolates in the absence of EBOR-CORM-1 for 48 hours 200 
and then applying EBOR-CORM-1 for 4 hours using both flow cytometry and crystal violet 201 
staining. We used only one EBOR-CORM-1 concentration, 0.5 mM, which resulted in clear 202 
reduction of PAO1 cultures (see results) alongside control treatment (no CORM).  203 
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In addition to measuring the effects of EBOR-CORM-1 in monocultures of each clinical 204 
isolate, we also quantified the effect of the CORM on mixtures of the CF clinical isolates 205 
from patient CF03. First, we prepared the clinical isolate starter cultures as described above, 206 
then we mixed the standardised monocultures together in three different ways: as a whole 207 
mix (all isolates mixed together in equal proportions), lineage A mix (all isolates classified as 208 
lineage A mixed together in equal proportions) and lineage B mix (all isolates classified as 209 
lineage B mixed together in equal proportions). All final mixes contained approximately 1 x 210 
10
8
 cells mL
-1
 before the application of 0.5 mM of EBOR-CORM-1. Each experiment was 211 
replicated 5 times. After 24 hours growth at 37 ¡C, bacterial densities were measured by 212 
using a Tecan infinite spectrophotometer: optical density measurements correlate well with 213 
the proportion of living cells measured with flow cytometer (Supplementary figure 1). 214 
Characterising bacterial virulence and growth  215 
To characterise production of the virulence factors pyocyanin and pyoverdine, all clinical 216 
isolates were grown in 200 µL of 10% LB media in round-bottomed 96-well microplates for 217 
48 hours at 37 ¡C (no shaking). After incubation, we measured the bacterial densities (OD 218 
600 nm) and centrifuged the microplate for 10 min. at 4000 rpm (11.5 g) in a swing rotor 219 
Eppendorf centrifuge. To measure pyocyanin and pyoverdine production, 150 µL of the 220 
supernatant of each well was transferred to flat-bottomed 96-well microplates and the 221 
absorbance spectrum measured with a spectrophotometer (Tecan infinite). Per capita 222 
pyocyanin production was measured for each isolate by measuring the absorbance of 223 
supernatant at 691 nm, and then standardizing by bacterial OD (Reszka et al., 2004). Per 224 
capita production of the iron-chelating siderophore, pyoverdine, was measured by using 225 
excitation-emission assay (O'Brien et al., 2017) where the fluorescence of each supernatant 226 
well was measured at 470 nm following excitation at 380 nm, using a Tecan infinite M200 227 
pro spectrophotometer. Also, OD was measured at 600 nm to quantify the ratio 228 
fluorescence/OD as a quantitative measure of per capita pyoverdine production (O'Brien et 229 
al., 2017). The isolate biofilm production was measured as described previously and growth 230 
as maximum density and growth rate h
-1
 during 24-hour growth period. Lastly, we also 231 
measured the in vivo virulence of each isolate by using wax moth model as described 232 
previously (O'Brien et al., 2017). 233 
                                                                                                    234 
Testing EBOR-CORM-1 antimicrobial activity in wax moth model in vivo 235 
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To test the efficacy of EBOR-CORM-1 to constrain bacterial infections in vivo, we used a 236 
wax moth larvae model (Galleria mellonella [Lepidoptera: Pyralidae], Livefood UK Ltd) and 237 
followed the infection methodology described previously (O'Brien et al., 2017). We chose 238 
three strains for infection experiments: PAO1, LESB58 and isolate 36 (Lineage B) from the 239 
clinical sample collection. Before infection, we first grew the selected P. aeruginosa isolates 240 
for 24 hours at 37 ¡C and subsequently diluted all cultures to approximately similar densities 241 
(equalling approximately 1 x 10
6
 cells mL
-1
 in 0.8% w:v NaCl). The virulence of every 242 
isolate was then tested in 16 independent wax moth larvae. We also infected 16 larvae with 243 
0.8% w/v NaCl salt solution to control for the damage caused by the injection itself. The 244 
larvae were injected with either 20 µL of one bacterial solution or NaCl buffer (Ònon-245 
infectedÓ) between the abdominal segments six and seven with a 1 mL Terumo syringe. After 246 
2 hours, 8 larvae from each bacterial infection or non-infection group were treated with 20 247 
µL injection of 500 µM EBOR-CORM-1, and the other 8 were injected with 0.8% w:v NaCl 248 
salt solution (control placebo) in the same location where the bacteria were originally 249 
injected. After infection, larvae were placed on individual wells of 24-well cell culture plates 250 
and the survival was monitored at 2-hour intervals for 3 days at 37 ¡C. Larvae were scored as 251 
dead when they did not respond to touch with forceps. Larvae that were still alive after 7 days 252 
from the infection were given a time of death of 168 hours. Every bacterial isolate was tested 253 
for three times. It was concluded that the EBOR-CORM-1 injection alone did not affect 254 
larval survival in the absence of bacteria (mortality similar between non-infected CORM-255 
injected larvae and non-infected CORM-free larvae: 5-10%). 256 
Statistical analysis 257 
All data were analysed with Generalized Mixed Models (factorial ANOVA) or regression 258 
analysis where bacterial densities (Figs. 2, 3 and 4b) or trait values (Fig. 4a; Supplementary 259 
figure 4) were explained with the presence and/or concentration of EBOR-CORM-1, CF 260 
isolate identity (isolate number) or CF lineage (A or B). All proportional data (%) were 261 
arcsine transformed before the analysis to meet the assumptions of parametric models.  262 
3. RESULTS 263 
Chemistry of EBOR-CORM-1 264 
The stability of EBOR-CORM-1 in the solid state was demonstrated by heating a sample of 265 
solid to 50 ¡C in air, and showing that there is very little difference in the carbonyl bands 266 
observed in ATR IR spectra measured at 1 hour intervals over a 3-hour period (Fig. 1A). In 267 
contrast, gas phase infrared analysis proved that CO release from EBOR-CORM-1can be 268 
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triggered by dissolution in water, phosphate buffer or LB media, or addition of water to a 269 
solution of the compound in an organic solvent (Fig. 1B).  270 
Solution phase monitoring of the CO stretches of the compound showed that there was no 271 
reaction with water over short periods of time, since dissolving EBOR-CORM-1 in water, 272 
immediately re-drying it on a vacuum line and then re-dissolving the resultant solid in 273 
chloroform yielded an IR spectra which matched that of the as-purified compound in 274 
chloroform (Fig. 1C). The only two observed IR bands in the CORM spectrum in water 275 
(2050 and 1943 cm
-1
) were therefore attributed to the molecular symmetry of the hydrated 276 
complex, rather than an immediate loss of CO upon contact with water. However, after 90 277 
min in water, a loss of these carbonyl bands was observed, and this was attributed to the 278 
release of all the CO from the complex (Fig. 1D).  279 
EBOR-CORM-1 activity against planktonic and biofilm cells of P. aeruginosa 280 
PAO1 281 
We found that applying EBOR-CORM-1 had generally negative effects on P. aeruginosa 282 
PAO1 growth both after 8 and 24 hours of application (F4, 25 = 50.9, p < 0.001 and F4, 25 = 283 
31.8, p < 0.001 for proportion of living cells after 8 and 24 hours, respectively, Fig. 2A) and 284 
that these negative effects increased along with the increasing concentration of applied 285 
EBOR-CORM-1 (regression analysis: F1, 24 = 43, p < 0.001 and F1, 24 = 35, p < 0.001 for 286 
proportion of living cells after 8 and 24 hours, respectively, Fig. 2A). Similarly, EBOR-287 
CORM-1 was highly effective against both established planktonic and biofilm P. aeruginosa 288 
PAO1 cultures (F4, 25 = 77.5, p < 0.001 and F4, 25 = 39.5, p < 0.001, respectively, Fig. 2A-B) 289 
and the antimicrobial activity of CORM increased in a density-dependent manner (regression 290 
analysis: F1, 24 = 92, p < 0.001 and F1, 24 = 54, p < 0.001, respectively, Fig. 2A-B). 291 
EBOR-CORM-1 activity against planktonic and biofilm cells of clinical P. 292 
aeruginosa cystic fibrosis isolates 293 
Similar to strain PAO1, we found that EBOR-CORM-1 had inhibitory effects on all tested 294 
clinical P. aeruginosa isolates after 8 hours of application of CORM (F1, 152 = 11969, p < 295 
0.001, Fig. 3A). While this effect did not depend on the lineage (CORM ! lineage: F1, 152 = 296 
1.4, p < 0.001), it varied between different clinical isolates (CORM ! isolate: F18, 152 = 11969, 297 
p < 0.001, Fig. 3A). In contrast, EBOR-CORM-1 had slightly positive effects on P. 298 
aeruginosa growth after 24 hours of application (F1, 152 = 256, p < 0.001, Fig. 3B) and this 299 
effect varied between different isolates (CORM ! strain: F18, 152 = 2.8, p = 0.001) being 300 
slightly stronger (i.e. positive) with isolates belonging to a lineage B (CORM ! lineage: F1, 301 
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152 = 24.9, p < 0.001, Fig. 3B). EBOR-CORM-1 also had negative effects when applied to 302 
established P. aeruginosa cell cultures (F1, 152 = 222, p < 0.001, Fig. 3C). However, these 303 
effects depended on the isolate (CORM ! isolate: F18, 152 = 2.8, p = 0.001) and the lineage 304 
(F1, 152 = 65.2, p = 0.001), reduction being relatively larger with isolates belonging to lineage 305 
A (Fig. 3C). In the case of established biofilms, EBOR-CORM-1 had a slightly positive 306 
effect (F1, 152 = 9.6, p = 0.002, Fig. 3D) and while this effect varied between different isolates 307 
(F18, 152 = 2.0, p = 0.01) it did not differ between the lineages (F1, 152 = 1.2, p = 0.265, 308 
respectively, Fig. 3D). Together these results suggest that compared to strain PAO1, EBOR-309 
CORM-1 effects varied more with the clinical P. aeruginosa isolates having negative, neutral 310 
or positive effects on bacterial growth depending on the isolate identity, lineage and the 311 
timing of CORM application. 312 
Linking EBOR-CORM-1 antimicrobial activity with clinical P. aeruginosa isolate 313 
virulence and growth 314 
We found that all the isolates belonging to a lineage A formed non-mucoid colonies (6 out of 315 
6), while most of the isolates belonging to a lineage B formed mucoid (i.e., mucus-like) 316 
colonies (11 out of 13) on LB plates (typical mucoid and non-mucoid colonies shown in 317 
supplementary figure 3). All clinical isolates differed from the non-mucoid PAO1 strain 318 
respective of their virulence and growth (Fig. 4A). More specifically, clinical isolates 319 
produced less pyoverdine (F1, 23 = 286, p < 0.001) and pyocyanin (F1, 23 = 170, p < 0.001) and 320 
grew slower (F1, 23 = 91, p < 0.00) and reached lower maximum densities in LB medium (F1, 321 
23 = 15.5, p = 0.001, Fig. 4A). However, clinical isolates produced a considerably larger 322 
amount of biofilm (F1, 23 = 21.7, p < 0.001) and showed very low virulence (high time to 323 
death) in wax moth larvae in vivo (F1, 23 = 1296, p < 0.001, Fig. 4A).  324 
When comparing the two CF lineages, we found that isolates belonging to a lineage B 325 
consistently outperformed the isolates belonging to a lineage A by producing more 326 
pyoverdine (F1, 18 = 6.06, p = 0.025), biofilm (F1, 18 = 15.08, p = 0.001) and by growing faster 327 
(F1, 18 = 22.35, p < 0.001) and to higher maximum densities (F1, 18 = 6.27, p = 0.023) in LB 328 
medium (Fig. 4A; Supplementary figure 4). However, lineages did not differ in pyocyanin 329 
production (F1, 18 = 1.99, p = 0.176) or virulence (F1, 18 = 1.03, p = 0.324; Fig. 4A; 330 
Supplementary figure 4). Across all clinical isolates, density reduction by CORM correlated 331 
negatively with biofilm formation (F1, 18 = 4.8, p = 0.042). Together these results suggest that 332 
clinical isolates differed from PAO1 and from each other respective to various life-history 333 
traits important for establishing an infection. 334 
EBOR-CORM-1 activity against clinical P. aeruginosa CF isolate co-cultures 335 
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Despite the observed isolate-specific variation in P. aeruginosa monocultures, EBOR-336 
CORM-1 was effective in reducing the growth of P. aeruginosa co-cultures after 24 hours of 337 
application (CORM: F1, 24 = 132, p < 0.001, Fig. 4B). Moreover, this reduction was the same 338 
regardless of whether the mix contained only one lineage or both lineages (CORM ! co-339 
culture: F2, 24 = 0.5, p = 0.612). These results suggest that intraspecific P. aeruginosa 340 
population heterogeneity makes the bacteria more susceptible to EBOR-CORM-1 treatment. 341 
EBOR-CORM-1 activity against P. aeruginosa strains in wax moth model 342 
We found that P. aeruginosa isolates differed in their virulence (time to death) from each 343 
other (F2, 24 = 12.2, p < 0.001): PAO1 and LESB58 strains were equally virulent, and both 344 
exhibited higher virulence than the clinical isolate 36 (killing larvae approximately in 17 345 
hours [PAO1], 36 hours [LESB58] and 92 hours [clinical isolate 36]; values averaged over 346 
both non-CORM and CORM treatments, Fig. 5). In contrast to in vitro results, application of 347 
EBOR-CORM-1 did not increase the survival of infected larvae (F1, 24 = 1.3, p = 0.257) with 348 
any of the infected strains (CORM ! strain: F2, 24 = 1.4, p = 0.273, Fig. 5). All larvae became 349 
highly pigmented (black throughout) during the infection regardless of the P. aeruginosa 350 
isolate. 351 
4. DISCUSSION 352 
Here we set out to study the antimicrobial activity of [NEt4][MnBr2(CO)4], EBOR-CORM-1, 353 
against clinical P. aeruginosa isolates in vitro. This CORM was chosen as a suitable 354 
representative of this class of molecule based on the aqueous solubility, facile synthesis 355 
(Angelici, 1964), content of a non-toxic metal core, and simple architecture which makes it 356 
akin to a Òparent compoundÓ for CORMs that have been engineered to possess sophisticated 357 
CO release mechanisms. In contrast to more complex CORMs, the molecule was shown to 358 
have a water activated mechanism of CO release, as seen in previous studies of [MX(CO)5]
-
 359 
species, where X is a halide (Zhang et al., 2009). Such water induced degradations are 360 
believed to proceed via a two-step pathway whereby water causes loss of the halide followed 361 
by formation of a dimer species; from which the CO is released. This may explain the 362 
changes in the IR spectra recorded in water when compared to chloroform, although the data 363 
do not directly match those for [Mn2Br2(CO)8] (El-Sayed and Kaesz, 1963), the product 364 
expect on loss of Br
-
 from EBOR-CORM-1. We found that while EBOR-CORM-1showed 365 
density-dependent antimicrobial activity against both planktonic and biofilm cells of the 366 
widely studied laboratory-adapted strain PAO1, these effects were more varied and weaker 367 
against clinical CF lung isolates. Regardless, EBOR-CORM-1 was efficient at reducing the 368 
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growth of CF isolate lineage mixes, which suggests that it could have therapeutic potential in 369 
controlling heterogeneous P. aeruginosa infections. Solutions of inactivated EBOR-CORM-1 370 
were essentially inactive against P. aeruginosa strain PAO1 (Supplementary figure 2) 371 
implying that, at least in this case, the observed activity was due to CO released from the 372 
complex rather than the residual metal salts (or indeed [NEt4]
+
). 373 
Similar to a study published by Murray et al. (2012), we found considerable variation in 374 
CORM antimicrobial activity between different clinical CF isolates, which depended whether  375 
we explored EBOR-CORM-1 effects on relatively short (8 hours) or long timescales (24 376 
hours) and if we compared CORM antimicrobial activity on actively growing and established 377 
cell cultures (after 48 hours of bacterial growth). Our results after 8 hours of EBOR-CORM-1 378 
application are very similar to a previous study (Murray et al., 2012) showing clear reduction 379 
in bacterial densities. However, this effect vanished by the 24 hour time point, and 380 
surprisingly, some bacterial isolate cultures reached higher optical densities in the presence 381 
compared to absence of CORM, which could have been due to increase in number of cells or 382 
expression of exoproducts that were picked up by OD600 nm (e.g. pyocyanin or alginate). 383 
The most likely explanation for this is that CORM effects were short-lived (Fig. 1), which 384 
allowed bacteria to recover and grow to high densities during 24 hours after application of 385 
CORM. However, when CORM effects were measured after 4 hours of application to 386 
established cell cultures, we could still observe clear reduction in mean bacterial densities. 387 
Together these results suggest that CORM effects could be seen up to 4 hours post 388 
application and that CORM could eradicate bacterial cells whether they are at exponential or 389 
stationary phase of their growth. Interestingly, CORM effects varied between clinical isolates 390 
and were clearer with the isolates belonging to lineage A. While Murray et al. (2012) did not 391 
observe clear variation in CORM effects against planktonic cell cultures, they found 392 
differences in CORM efficiency in eradicating bacterial biofilms. This is also consistent with 393 
our data and reinforces the hypothesis that P. aeruginosa clinical isolates are likely to 394 
respond differently to CORM therapies.  395 
To explore clinical isolate variation in more detail, we compared differences in bacterial 396 
virulence and growth traits between the PAO1 and clinical CF lung isolates. We found that 397 
relative to strain PAO1, clinical CF isolates grew slower, had lowered virulence and 398 
produced lower amounts of pyoverdine and pyocyanin, which are important virulence factors 399 
(O'Brien et al., 2017). This is consistent with previous research and typical for P. aeruginosa 400 
isolates retrieved from chronic lung infections (Smith et al., 2006;Folkesson et al., 401 
2012;Marvig et al., 2013;Williams et al., 2015). The clinical isolates produced much more 402 
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biofilm compared to strain PAO1 and biofilm formation was the highest in the isolates 403 
belonging to lineage B. Biofilms could potentially provide a protective function against 404 
CORMs. Biofilms often have much higher antibiotic resistance than their aquatic 405 
counterparts (Stewart and William Costerton, 2001) and there are multiple reasons for this. 406 
First, antibiotics might be ineffective because the biofilm acts as a diffusion barrier (de Beer 407 
et al., 1997). Second, subpopulations within the biofilm can sometimes differentiate into a 408 
highly protected phenotypes that can repopulate the biofilms (Cochran et al., 2000). Third, 409 
the biofilm might change the chemical microenvironment, forming zones of nutrient and 410 
oxygen depletion or waste accumulation that prevents the antibiotics from functioning 411 
optimally (de Beer et al., 1994). Although we did not explore this specifically, clinical 412 
isolates belonging to a lineage A were more susceptible to CORMs and produced relatively 413 
less biofilm compared to strains belonging to a lineage B. Thus, overall a negative correlation 414 
was found between density reduction by CORM and biofilm formation. Our results therefore 415 
suggest that biofilm might provide a protective function against the CORM. 416 
Despite the isolate variations observed in bacterial monocultures, EBOR-CORM-1was 417 
effective at reducing the growth of P. aeruginosa clinical isolate mixed cultures. One 418 
explanation for this is that, in addition to CORM, P. aeruginosa growth was limited by 419 
antagonistic intraspecific species interactions in co-cultures. P. aeruginosa has been shown to 420 
exert both facilitative and antagonistic effects on each other via siderophore (Harrison et al., 421 
2008) and bacteriocin (Ghoul et al., 2015) production. In our case, all the clinical isolates 422 
were derived from the same Liverpool Epidemic Strain clonal lineage and therefore likely 423 
carried the same siderophore and bacteriocin genes. Additionally, resource competition is 424 
likely to further limit P. aeruginosa growth both in CF lungs and simplified laboratory 425 
microcosms. As a result, even though some clinical strains were relatively insensitive to 426 
EBOR-CORM-1, their growth could have been constrained by competition with the other 427 
strains in co-cultures. We found that this was the case for all strain mixes regardless if the 428 
strains belonged to a lineage A, B or them both. This suggests that the susceptibility of the 429 
lineages measured in monocultures did not predict the susceptibility of isolate mixes within 430 
or between lineages. However, such antagonism was not observed in the absence of EBOR-431 
CORM-1, which suggests that CORM-triggered antagonistic intraspecific interactions in P. 432 
aeruginosa co-cultures. Mechanistically, this could have been driven by competition sensing 433 
in response to CORM-mediated cell damage in P. aeruginosa populations (Cornforth and 434 
Foster, 2013). However, this needs to be confirmed in future experiments. Interestingly, all 435 
the clinical strains we used originated from a single CF patient and interactions between them 436 
thus reflect the realistic ecology of CF lungs. In the future, it would be useful to determine 437 
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pairwise interactions between these CF strains and look at CORM effects on other coexisting 438 
bacterial species observed in CF infections (Folkesson et al., 2012). 439 
We found that EBOR-CORM-1 had no clear therapeutic benefits in the wax moth infection 440 
model. There are several potential explanations for this. First, EBOR-CORM-1 had limited 441 
long-term activity when in contact with water. As a result, the bactericidal effect may only 442 
have elicited lag in the initial phase of bacterial growth and proliferation within the wax 443 
moths. Second, insect tissue is not homogeneous and it is possible that we failed to deliver 444 
the CORM to the specific area of infection, or that bacteria were able to colonise new areas 445 
that were not exposed to the CORM. Third, insects differ from laboratory media (such as LB) 446 
as a bacterial growth environment, which could also affect pathogen virulence. For example, 447 
it has been recently demonstrated that plant versus animal based growth media can have 448 
physiological effects on bacterial virulence (Ketola et al., 2016) and that LB media does not 449 
adequately reflect P. aeruginosa growth on lung tissue (Harrison et al., 2014;Harrison and 450 
Diggle, 2016). Hence, the wax moth injection model might not reliably reflect the virulence 451 
of CF isolates derived from chronic infections. However, it is also the case that many of the 452 
affordable and available CF infection animal models do not truly reflect the real CF lung 453 
disease environment. It remains to be established whether CORM therapy could be applied in 454 
the context of CF lung infections. It is possible, for example, that it might be more suitable 455 
for treating topical infections such as burn wounds, for which better animal models are 456 
available (Rumbaugh et al., 2012).  457 
Further work is also needed to understand the mode of action of EBOR-CORM-1. While 458 
respiratory oxidases and globins at heme targets are generally considered the prime targets of 459 
CO and CORMs (Wareham et al., 2015), it has been demonstrated that CORMs can have 460 
multiple different other targets (Wilson et al., 2015). For example, CO also binds to the di-461 
iron site in bacterial NO reductases and to iron, copper, and nickel sites in certain microbial 462 
proteins such as CO dehydrogenase (Lu et al., 2004;Wasser et al., 2005). In some cases, 463 
CORMs might have intracellular targets but their accumulation within the cells can be very 464 
weak (Tinajero-Trejo et al., 2016). Moreover, in the future it would be important to test if 465 
EBOR-CORM-1 is cytotoxic to eukaryotic cells. The concentration we used are in line with 466 
previously published work where no, or very mild, cytotoxic effects were observed (Murray 467 
et al., 2012). We are currently conducting experiments to validate this independently and to 468 
understand how EBOR-CORM-1interacts with bacterial cells. While, our wax moth assays 469 
show that the concentrations we used had no negative effects on short-term insect viability, 470 
more detailed cytotoxicity assays are needed in the future. Lastly, the low solubility of 471 
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EBOR-CORM-1 in water, and its activation in this medium, is problematic for delivery and 472 
activation at specific sites within patients. In addition to chemically increasing the molecule 473 
stability, CORMs could be enclosed in microvesicles (van Dommelen et al., 2012) to ensure 474 
more efficient antimicrobial activity and drug delivery.  475 
In conclusion, our results show that EBOR-CORM-1 shows antimicrobial activity against 476 
both planktonic and biofilm cells of P. aeruginosa strain PAO1 but that these effects are 477 
more varied and less pronounced against clinical CF lung isolates in monocultures. In 478 
contrast, more heterogeneous P. aeruginosa populations comprising intraspecific phenotypic 479 
variants were more susceptible to CORM treatment. This potentially has wider implications 480 
in the testing of novel therapeutics. At present, this is done almost exclusively using clonal P. 481 
aeruginosa populations. Our observations suggest that testing carried out on more 482 
heterogeneous populations of P. aeruginosa, more closely resembling those found in the CF 483 
lung, may give different and sometimes more promising results. 484 
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 493 
Figure 1. The stability of1 EBOR-CORM-1. Panel A shows the IR spectra of EBOR-CORM-494 
1 upon heating at 50¡ C for 0 hours (black line), for 1 hours (red line), for 2 hours (blue) and 495 
for 3 hours (pink). The structure of the EBOR-CORM-1 is shown in inset on the left. Panel B 496 
shows the gas phase IR spectra of EBOR-CORM-1 in chloroform with added water where 497 
the * indicates a band from chloroform. Panel C shows the IR spectra of EBOR-CORM-1 in 498 
chloroform (top) and water (bottom) and panel D the IR spectra of CO in water after 1 min 499 
(top) and 90 min (bottom) dissolution. All frequencies given are in cm
-1
.  500 
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 501 
 502 
Figure 2. The EBOR-CORM-1 effects on planktonic and biofilm cells of P. aeruginosa 503 
PAO1. In panel A, different lines denote for cell densities after 8 hours (blue line) and 24 504 
hours (green line) of EBOR-CORM-1 application and EBOR-CORM-1 effects on established 505 
cell cultures (red line) in different CORM concentrations. Panel B shows EBOR-CORM-1 506 
effects on PAO1 biofilms in different CORM concentrations. The R
2
 denotes for the fit of 507 
regression with our data, and in panel B, bars denote for  ±1 s.e.m. 508 
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 509 
 510 
Figure 3. The EBOR-CORM-1 effects on planktonic and biofilm cells of clinical P. 511 
aeruginosa CF isolates. Panels A and B show the proportion of living cells after 8 hours and 512 
24 hours of EBOR-CORM-1 application, respectively. Panel C and D show the EBOR-513 
CORM-1 effects on established cell cultures and biofilms, respectively. In all panels, bars 514 
denote for  ±1 s.e.m. 515 
 516 
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517 
  518 
Figure 4. Differences in P. aeruginosa growth and virulence trait variation between PAO1 519 
and clinical CF isolates (panel A) and EBOR-CORM-1 effects on clinical CF isolate lineage 520 
mixes (panel B). In panel A, different colours denote for pyocyanin (blue) and pyoverdine 521 
(green) production, time to death (black), growth rate (purple), maximum density (yellow) 522 
and biofilm production for clinical isolates belonging to lineages A and B. The dashed line 523 
shows the mean performance of PAO1 strain. Panel B shows EBOR-CORM-1 effect on 524 
clinical CF isolate mixes after 24 hours of CORM application. In panel A, bars denote for  ±1 525 
s.e.m., and in panel B, extreme values around lower and upper quartile (black line shows the 526 
median).  527 
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 528 
Figure 5. The EBOR-CORM-1 activity against three P. aeruginosa strains in wax moth 529 
model. Boxplots show larval survival in the absence (light grey) and presence (blue) of 530 
EBOR-CORM-1 for PAO1, LESB58 and clinical isolate #36 (lineage B). Bars show extreme 531 
values around lower and upper quartile and black lines show the median.  532 
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